FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Osoba

Research Profile

Concepts & Ideas

Activities & Behaviors

Questionnaires

Disorders

Procedures

Chemicals & Drugs

Geographic Areas

Canada

Co-author Network

Publications

TOP 3
John T Maringwa; Francesca Martinelli; David Osoba; Chantal Quinten; Bryce B Reeve; Jolie Ringash; Egbert F Smit; Martin J Taphoorn; Jan P van Meerbeeck; Jurgen Vercauteren; Joachim Weis; Andrew Bottomley; Charles S Cleeland; Corneel Coens; Henning Flechtner; Carolyn C Gotay; Elfriede Greimel; Madeleine King; Joseph Schmucker-Von Koch
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
Francesca Martinelli; Tito Mendoza; David Osoba; Chantal Quinten; Bryce B Reeve; Jolie Ringash; Qiuling Shi; Martin J Taphoorn; Jurgen Vercauteren; Joachim Weis; andrew bottomley; Charles S Cleeland; Corneel Coens; Henning Flechtner; Carolyn C Gotay; Elfriede Greimel; Madeleine King; Joseph Schmucker-Von Koch; John T Maringwa
Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.
John Maringwa; F Martinelli; David Osoba; C Quinten; B B Reeve; J Ringash; J Schmucker-Von Koch; R Stupp; Martin J B Taphoorn; M J Van Den Bent; J Weis; andrew bottomley; Charles S Cleeland; Corneel Coens; Henning Flechtner; Carolyn C Gotay; Elfriede Greimel; M King
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Osoba (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: John T Maringwa; Francesca Martinelli; David Osoba; Chantal Quinten; Bryce B Reeve; Jolie Ringash; Egbert F Smit; Martin J Taphoorn; Jan P van Meerbeeck; Jurgen Vercauteren; Joachim Weis; Andrew Bottomley; Charles S Cleeland; Corneel Coens; Henning Flechtner; Carolyn C Gotay; Elfriede Greimel; Madeleine King; Joseph Schmucker-Von Koch
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19(11):1753-60.
2011: Francesca Martinelli; Tito Mendoza; David Osoba; Chantal Quinten; Bryce B Reeve; Jolie Ringash; Qiuling Shi; Martin J Taphoorn; Jurgen Vercauteren; Joachim Weis; andrew bottomley; Charles S Cleeland; Corneel Coens; Henning Flechtner; Carolyn C Gotay; Elfriede Greimel; Madeleine King; Joseph Schmucker-Von Koch; John T Maringwa
Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.
Expert review of pharmacoeconomics & outcomes research 2011;11(5):587-99.
2011: John Maringwa; F Martinelli; David Osoba; C Quinten; B B Reeve; J Ringash; J Schmucker-Von Koch; R Stupp; Martin J B Taphoorn; M J Van Den Bent; J Weis; andrew bottomley; Charles S Cleeland; Corneel Coens; Henning Flechtner; Carolyn C Gotay; Elfriede Greimel; M King
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(9):2107-12.
2010: Madeleine T King; David Osoba; Martin Stockler; Joanna Thompson; David Cella; David Eton; Amy R Eisenstein
Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire.
Patient related outcome measures 2010;1():119-26.
2010: Madeleine T King; Martin R Stockler; David F Cella; David Osoba; David T Eton; Joanna Thompson; Amy R Eisenstein
Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G.
Journal of clinical epidemiology 2010;63(3):270-81.
2009: Chantal Quinten; Corneel Coens; Murielle Mauer; Sylvie Comte; Mirjam A G Sprangers; Charles S Cleeland; David Osoba; Kristin Bjordal; andrew bottomley
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.
The lancet oncology 2009;10(9):865-71.
2009: andrew bottomley; Chantal Quinten; Corneel Coens; Francesca Martinelli; Murielle Mauer; John Maringwa; Charles S Cleeland; Henning Flechtner; Carolyn Gotay; Eva Greimel; Madeleine King; David Osoba; Martin J B Taphoorn; Bryce B Reeve; Jolie Ringash; Joseph Schmucker-Von Koch; Joachim Weis
Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative.
European journal of cancer care 2009;18(2):105-7.
2007: Michael D Brundage; David Osoba; Andrea Bezjak; Dongsheng Tu; Michael Palmer; Joseph L Pater
Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(32):5078-81.
2007: David Osoba; Andrea Bezjak; Michael D Brundage; Joseph L Pater
Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2007;10 Suppl 2():S138-45.
2007: Murielle E L Mauer; Roger Stupp; Martin J B Taphoorn; Corneel Coens; David Osoba; Christine Marosi; R Wong; O de Witte; J G Cairncross; Fabio Efficace; René-Olivier Mirimanoff; Peter A Forsyth; Martin J van den Bent; M Weller; andrew bottomley
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study.
British journal of cancer 2007;97(3):302-7.
2007: Fabio Efficace; David Osoba; Carolyn C Gotay; Mirjam Sprangers; Corneel Coens; andrew bottomley
Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):775-81.
2007: David Osoba
Health-related quality of life and predicting survival in cancer: not a simple matter.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(4):353-5.
2007: David Osoba
Translating the science of patient-reported outcomes assessment into clinical practice.
Journal of the National Cancer Institute. Monographs 2007;(37):5-11.
2006: F Reed Johnson; A Brett Hauber; David Osoba; Ming-Ann Hsu; John Coombs; Catherine Copley-Merriman
Are chemotherapy patients' HRQoL importance weights consistent with linear scoring rules? A stated-choice approach.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2006;15(2):285-98.
2006: David Osoba; Ming-Ann Hsu; Catherine Copley-Merriman; John Coombs; F Reed Johnson; Brett Hauber; Ranjani Manjunath; Amanda Pyles
Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2006;15(2):273-83.
2005: Martin J B Taphoorn; Roger Stupp; Corneel Coens; David Osoba; Rolf-Dieter Kortmann; Martin J van den Bent; Warren Mason; René-Olivier Mirimanoff; Brigitta Baumert; Elizabeth Eisenhauer; Peter A Forsyth; andrew bottomley
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
The lancet oncology 2005;6(12):937-44.
2005: Maurizio Tonato; Rebecca A Clark-Snow; David Osoba; Albano Del Favero; Enzo Ballatori; Sussanne Borjeson
Emesis induced by low or minimal emetic risk chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(2):109-11.
2005: Steven M Grunberg; David Osoba; Paul J Hesketh; Richard J Gralla; Sussanne Borjeson; Bernardo L Rapoport; Andreas du Bois; Maurizio Tonato
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(2):80-4.
2005: David Osoba; Andrea Bezjak; Michael D Brundage; Benny Zee; Dongsheng Tu; Joseph L Pater
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.
European journal of cancer (Oxford, England : 1990) 2005;41(2):280-7.
2004: Susan E Krown; Donald W Northfelt; David Osoba; J Simon Stewart
Use of liposomal anthracyclines in Kaposi's sarcoma.
Seminars in oncology 2004;31(6 Suppl 13):36-52.
2004: Andrea Bezjak; Dongsheng Tu; Monica Bacon; David Osoba; Benny Zee; Gavin Stuart; Josee-Anne Roy; Martine Piccart; Elizabeth Eisenhauer
Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4595-603.
2004: George Rodrigues; Andrea Bezjak; David Osoba; Pamela Catton; Debbie Tsuji; D Taylor; P Warde
The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2004;13(7):1235-46.
2003: Fabio Efficace; andrew bottomley; David Osoba; Carolyn C Gotay; Henning Flechtner; Sven D'haese; Alfredo Zurlo
Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3502-11.
2003: Charles G Martin; Edward B Rubenstein; Linda S Elting; Young Jun Kim; David Osoba
Measuring chemotherapy-induced nausea and emesis.
Cancer 2003;98(3):645-55.
2003: Jeff A Sloan; David Cella; Marlene H Frost; Gordon Guyatt; David Osoba
Quality of life III: translating the science of quality-of-life assessment into clinical practice-an example-driven approach for practicing clinicians and clinical researchers.
Clinical therapeutics 2003;25 Suppl D():D1-5.
2002: M Keyes; T J Keane; David Osoba; Graeme G Duncan; N Phillips
Health-related quality of life in patients on radiotherapy waiting lists.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2002;14(4):329-30.
2002: David Osoba; Dennis J Slamon; Michael Burchmore; Maureen Murphy
Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3106-13.
2002: David Osoba
A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results.
Medical care 2002;40(6 Suppl):III31-8.
2002: Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Methods to explain the clinical significance of health status measures.
Mayo Clinic proceedings. Mayo Clinic 2002;77(4):371-83.
2001: David Osoba; Donald W Northfelt; D W Budd; D Himmelberger
Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine.
Cancer investigation 2001;19(6):573-80.
2000: David Osoba; M Brada; M D Prados; W K Yung
Effect of disease burden on health-related quality of life in patients with malignant gliomas.
Neuro-oncology 2000;2(4):221-8.
2000: David Osoba; M Brada; W K Yung; M D Prados
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
European journal of cancer (Oxford, England : 1990) 2000;36(14):1788-95.
2000: W K Alfred Yung; Robert Albright; J Olson; R Fredericks; K Fink; Michael D Prados; M Brada; A Spence; R J Hohl; W Shapiro; Michael Glantz; Harry S Greenberg; R G Selker; N A Vick; Roy Rampling; H Friedman; P Phillips; Janet Bruner; N Yue; David Osoba; Sara Zaknoen; Victor Levin
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
British journal of cancer 2000;83(5):588-93.
2000: David Osoba
Effects of temozolomide in malignant brain tumours.
Lancet 2000;356(9226):342.
2000: BD Norris; Kathleen I Pritchard; K James; J Myles; K Bennett; S Marlin; JR Skillings; Brian Findlay; Theodore A Vandenberg; P Goss; Jean Latreille; Leona Rudinskas; WS Lofters; Maureen Trudeau; David Osoba; A Rodgers
Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2385-94.
2000: David Osoba; M Brada; W K Yung; M Prados
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(7):1481-91.
2000: David Osoba
Health-related quality-of-life assessment in clinical trials of supportive care in oncology.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000;8(2):84-8.
2000: DA Revicki; David Osoba; D Fairclough; I Barofsky; Rick Berzon; Nancy Kline Leidy; M Rothman
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2000;9(8):887-900.
1999: David Osoba
What has been learned from measuring health-related quality of life in clinical oncology.
European journal of cancer (Oxford, England : 1990) 1999;35(11):1565-70.
1999: Richard J Gralla; David Osoba; Mark G Kris; P Kirkbride; Paul J Hesketh; L W Chinnery; Rebecca A Clark-Snow; D P Gill; S Groshen; Steven M Grunberg; Jim M Koeller; Gary R Morrow; Edith A Perez; J H Silber; David G Pfister
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2971-94.
1999: Nevin Murray; Robert B Livingston; Frances A Shepherd; K James; Benny Zee; A Langleben; Michael J Kraut; James Bearden; J Wendall Goodwin; C Grafton; A Turrisi; D Walde; H Croft; David Osoba; Jon Ottaway; David R Gandara
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2300-8.
1999: David Osoba; Michael Burchmore
Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin).
Seminars in oncology 1999;26(4 Suppl 12):84-8.
1999: David Osoba; I Tannock
Measuring health-related quality of life.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2293.
1999: Martin R Stockler; David Osoba; P Corey; P J Goodwin; I F Tannock
Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life Questionnaire.
Journal of clinical epidemiology 1999;52(7):653-66.
1999: David Osoba; Ian F Tannock; DS Ernst; AJ Neville
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1654-63.
1999: David Osoba
Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1999;12():132-7.
1999: Joel B Epstein; S Emerton; D A Kolbinson; Nhu D Le; N Phillips; Peter Stevenson-Moore; David Osoba
Quality of life and oral function following radiotherapy for head and neck cancer.
Head & neck 1999;21(1):1-11.
1998: Niels Neymark; W Kiebert; K Torfs; linda davies; P Fayers; bruce hillner; R Gelber; G Guyatt; P Kind; D Machin; E Nord; David Osoba; D Revicki; Kevin Schulman; K Simpson
Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1317-33.
1998: Jane A Buxton; M White; David Osoba
Patients' experiences using a computerized program with a touch-sensitive video monitor for the assessment of health-related quality of life.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1998;7(6):513-9.
1998: JJ Rusthoven; David Osoba; Charles Butts; Louise Yelle; H Findlay; A Grenville
The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(4):389-95.
1998: Joseph L Pater; David Osoba; Benny Zee; WS Lofters; M Gore; E Dempsey; Michael Palmer; C Chin
Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1998;7(3):273-8.
1998: David Osoba; B Zee
Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group.
Statistics in medicine 1998;17(5-7):603-12.
1998: Jürg Bernhard; David Cella; Alan Coates; L Fallowfield; Patricia Anne Ganz; C M Moinpour; P Mosconi; David Osoba; R John Simes; Christoph Hürny
Missing quality of life data in cancer clinical trials: serious problems and challenges.
Statistics in medicine 1998;17(5-7):517-32.
1998: Jean Latreille; Joseph L Pater; D Johnston; Francis Laberge; D Stewart; JJ Rusthoven; Paul J Hoskins; Brian Findlay; E McMurtrie; Louise Yelle; C Williams; D Walde; S Ernst; H Dhaliwal; David Warr; Frances A Shepherd; D Mee; L Nishimura; David Osoba; Benny Zee
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1174-8.
1998: Martin R Stockler; David Osoba; P Goodwin; P Corey; Ian F Tannock
Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer.
Journal of clinical epidemiology 1998;51(2):137-45.
1998: David Osoba; George Rodrigues; J Myles; Benny Zee; Joseph L Pater
Interpreting the significance of changes in health-related quality-of-life scores.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):139-44.
1997: Joseph L Pater; Benny Zee; Michael Palmer; D Johnston; David Osoba
Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(5):410-3.
1997: David Osoba; N K Aaronson; M Muller; Kommer C A Sneeuw; Ming-Ann Hsu; W K Yung; M Brada; E Newlands
Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.
Journal of neuro-oncology 1997;34(3):263-78.
1997: David Osoba; Benny Zee; David Warr; Jean Latreille; L Kaizer; Joseph L Pater
Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(4):307-13.
1997: Alan Coates; F Porzsolt; David Osoba
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1025-30.
1997: Kommer C A Sneeuw; Neil K Aaronson; David Osoba; M J Muller; Ming-Ann Hsu; W K Yung; M Brada; E S Newlands
The use of significant others as proxy raters of the quality of life of patients with brain cancer.
Medical care 1997;35(5):490-506.
1997: J Dancey; Benny Zee; David Osoba; M Whitehead; F Lu; L Kaizer; Jean Latreille; Joseph L Pater
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1997;6(2):151-8.
1997: David Osoba; Neil Aaronson; B Zee; Mirjam Sprangers; A te Velde
Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1997;6(2):103-8.
1997: David Osoba
Current applications of health-related quality-of-life assessment in oncology.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(2):100-4.
1997: David Osoba; Benny Zee; Joseph L Pater; David Warr; Jean Latreille; L Kaizer
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):116-23.
1996: M Staquet; R Berzon; David Osoba; D Machin
Guidelines for reporting results of quality of life assessments in clinical trials.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1996;5(5):496-502.
1996: David Osoba; Benny Zee; David Warr; L Kaizer; Jean Latreille; Joseph L Pater
Quality of life studies in chemotherapy-induced emesis.
Oncology 1996;53 Suppl 1():92-5.
1996: Ian F Tannock; David Osoba; Martin R Stockler; D S Ernst; A J Neville; Malcolm J Moore; G R Armitage; J J Wilson; P M Venner; C M Coppin; K C Murphy
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1756-64.
1996: David Osoba; N K Aaronson; M Muller; Kommer C A Sneeuw; Ming-Ann Hsu; W K Yung; M Brada; E Newlands
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1996;5(1):139-50.
1996: David Osoba; J Dancey; Benny Zee; J Myles; Joseph L Pater
Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group.
Journal of the National Cancer Institute. Monographs 1996;(20):107-11.
1996: David Osoba
Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy.
Cancer treatment reviews 1996;22 Suppl A():69-73.
1995: David Osoba
Health-related quality of life as a treatment endpoint in metastatic breast cancer.
The Canadian journal of oncology 1995;5 Suppl 1():47-53.
1995: David Osoba; D G Warr; M I Fitch; L Nakashima; B Warren
Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.
The Canadian journal of oncology 1995;5(3):381-400.
1995: M I Fitch; David Osoba; N Iscoe; J P Szalai
Predicting psychological distress in patients with cancer: conceptual basis and reliability evaluation of a self-report questionnaire.
Anticancer research 1995;15(4):1533-42.
1995: David Osoba
Measuring the effect of cancer on health-related quality of life.
PharmacoEconomics 1995;7(4):308-19.
1995: David Osoba; J E Till; J L Pater; J R Young
Health-related quality of life: measurement and clinical application. A workshop report.
The Canadian journal of oncology 1995;5(1):338-43.
1994: J Schaafsma; David Osoba
The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1994;3(6):413-24.
1994: David Osoba; Benny Zee; Joseph L Pater; David Warr; L Kaizer; Jean Latreille
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1994;3(5):353-64.
1994: J E Till; David Osoba; J L Pater; J R Young
Research on health-related quality of life: dissemination into practical applications.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1994;3(4):279-83.
1994: Joseph L Pater; L Slamet; Benny Zee; David Osoba; David Warr; JJ Rusthoven
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1994;2(3):161-6.
1994: David Osoba; Nevin Murray; Karen Gelmon; H Karsai; M Knowling; A Shah; M McLaughlin; E Fetherstonhaugh; R Page; C A Bowman
Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy.
Oncology (Williston Park, N.Y.) 1994;8(4):61-5; discussion 65-6, 69.
1994: Malcolm J Moore; David Osoba; K Murphy; Ian F Tannock; A Armitage; Brian Findlay; C Coppin; A Neville; P Venner; J Wilson
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):689-94.
1994: David Osoba
Lessons learned from measuring health-related quality of life in oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):608-16.
1994: David Osoba; Nevin Murray; Karen Gelmon; H Karsai; M A Knowling; A Shah; M J Mclaughlin; E M Fetherstonhaugh; R Page; C A Bowman
Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy.
Oncology (Williston Park, N.Y.) 1994;8(3):43-9; discussion 49-50, 52.
1993: David Osoba; J Pater
Assessing quality of life in clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(6):520.
1993: David Osoba
Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology.
Cancer treatment reviews 1993;19 Suppl A():43-51.
1992: David Osoba; P R Band; J H Goldie; Joseph Michael Connors; Karen Gelmon; M A Knowling; E M Fetherstonhaugh
Efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 3():57-62.
1992: Anna Sadura; Joseph L Pater; David Osoba; M Levine; M Palmer; K Bennett
Quality-of-life assessment: patient compliance with questionnaire completion.
Journal of the National Cancer Institute 1992;84(13):1023-6.
1992: David Osoba
The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1992;1(3):211-8.
1992: David Osoba; P R Band; Joseph Michael Connors; J H Goldie; M A Knowling; E M Fetherstonhaugh
Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin.
Seminars in oncology 1992;19(2 Suppl 5):25-9; discussion 30-1.
1992: David Warr; A Wilan; P Venner; Joseph L Pater; L Kaizer; Francis Laberge; Jean Latreille; D Stewart; G O'Connell; David Osoba
A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):33-6.
1992: David Osoba
Intensive chemotherapy for extensive-stage small-cell lung cancer (SCLC)
Cancer investigation 1992;10(2):185-6.
1991: JJ Rusthoven; Joseph L Pater; L Kaizer; K Wilson; David Osoba; Jean Latreille; Brian Findlay; WS Lofters; David Warr; Francis Laberge
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(9):681-6.
1991: Nevin Murray; A Shah; David Osoba; R Page; H Karsai; C Grafton; K Goddard; Randall Fairey; N Voss
Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1632-8.
1991: David Warr; A Willan; S Fine; K Wilson; A Davis; C Erlichman; JJ Rusthoven; WS Lofters; David Osoba; Francis Laberge
Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
Journal of the National Cancer Institute 1991;83(16):1169-73.
1991: David Osoba
Recommendations of the National Conference on Community Cancer Programs: a vision for the future.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1991;144(11):1433-6.
1991: David Osoba; A D Flores; J H Hay; F Wong; M Maher
Phase I study of concurrent carboplatin and radiotherapy in previously untreated patients with stage III and IV head and neck cancer.
Head & neck 1991;13(3):217-22; discussion 222-3.
1991: Nevin Murray; David Osoba; A Shah; R Page; H Karsai; C Little
Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen.
Journal of the National Cancer Institute 1991;83(3):190-4.
1990: David Osoba
Measuring quality of life.
Progress in clinical and biological research 1990;354B():233-40.
1988: David Osoba; C Erlichman; A R Willan; M L Brigden; P Geggie; J L Pater; J J Rusthoven; K S Wilson
Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy.
Clinical and investigative medicine. Médecine clinique et experimentale 1988;11(5):377-9.
1988: P Coy; I Hodson; D G Payne; W K Evans; Ronald Feld; A S MacDonald; David Osoba; J L Pater
The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial.
International journal of radiation oncology, biology, physics 1988;14(2):219-26.
1987: Ronald Feld; W K Evans; P Coy; I Hodson; A S MacDonald; David Osoba; D Payne; W Shelley; Joseph L Pater
Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(9):1401-9.
1986: W K Evans; Ronald Feld; N Murray; Joseph L Pater; W Shelley; A Willan; David Osoba; M Levitt; P Coy; I Hodson
The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
Seminars in oncology 1986;13(3 Suppl 3):10-6.